Pharmaceuticals

Sterne Kessler works with branded pharmaceutical companies as well as biosimilars and generic drug companies to protect, enforce, and defend their intellectual property.

Sterne Kessler’s pharmaceuticals practice integrates deep technical knowledge with legal acumen to develop robust patent portfolios, address patent validity challenges at the PTAB, and handle high-profile patent litigation, including Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) matters. We work effectively with our clients to align IP with corporate strategy, and understand the advancements in life sciences that are shaping the IP landscape.Prescription & OTC DrugsOur pharmaceuticals team helps small molecule drug companies across the full range of IP—from patent prosecution and strategy, to opinions and litigation.Infectious Disease TreatmentsSterne Kessler protects and defends drug and vaccine innovations developed to fight against infectious diseases.Generic Drug DevelopmentWe work with generic drug developers to navigate the interface between patent law and the FDA approval process, as well as patent litigation and Abbreviated New Drug Application (ANDA) matters.

Articles

July 21, 2026

Clearing the Path: How Freedom-To-Operate Analysis Should Drive Life Sciences Investment Decisions

Sterne, Kessler, Goldstein & Fox

Firm News

July 20, 2026

Sterne Kessler and Directors Shortlisted in 10 Categories for the 2026 Life Sciences Americas Awards

Sterne, Kessler, Goldstein & Fox

Articles

July 16, 2026

When AI Drives Discovery — Patents and Drug Development

Westlaw Today

In the News

July 10, 2026

Fed. Circ. Won’t Rethink Corcept Patent Loss in Teva Case

Law360

Articles

July 8, 2026

Coordinating Life Sciences IP Strategies in the U.S. and EU

Law360